Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | AceLink, Alebund, Anakuria, Galapagos, Healx, Janssen, Kadmon, Otsuka, Poxel, Reata, Regulus, Sanofi, Xortx

The Autosomal Dominant Polycystic Kidney Disease (ADPKD) market size in seven major markets was USD 1,077 million in 2021, which is further expected to increase significantly by 2032. As per DelveInsight, the Autosomal Dominant Polycystic Kidney Disease Market is anticipated to evolve immensely in the coming years owing to the expected launch of potential therapies assisted by an increase in the diagnosed prevalent population in the 7MM.

DelveInsight's "Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Autosomal Dominant Polycystic Kidney Disease Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Autosomal Dominant Polycystic Kidney Disease therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Autosomal Dominant Polycystic Kidney Disease treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Overview
Polycystic kidney disease (PKD) is an inherited genetic disorder where fluid-filled sacs, called cysts, develop in the kidneys. Unlike simple kidney cysts that are harmless, cysts in PKD enlarge the kidneys, changing their shape and interfering with their ability to filter waste products from the blood. It reduces kidney function eventually leading to kidney failure. Cysts may also develop in other organs besides the kidney, particularly the liver, pancreas, spleen, ovaries, and large bowel. There are two major forms of polycystic kidney disease that are distinguished by the usual age of onset and the pattern in which it is passed through families.

Most cases of PKD have an autosomal dominant pattern of inheritance, seen in 9 out of every 10 individuals with PKD. The autosomal dominant form has signs and symptoms that typically begin in adulthood, although cysts in the kidney are often present from birth or childhood. ADPKD can be further divided into type 1 and type 2, depending on the genetic cause. The autosomal recessive form of PKD is rarer and is often lethal early in life. The signs and symptoms of this condition are usually apparent at birth or in early infancy.

ADPKD is mainly caused by mutations in two genes: PKD1 (16p13.3) and PKD2 (4q21). According to various country-specific organizations, approximately 85% of cases are of the PKD1 gene in mutation-specific cases of ADPKD, and the remaining is of the PKD2 gene.

The rate at which cysts enlarge and cause a loss of kidney function varies widely and may be influenced by mutations in other genes that have not been identified.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Key Facts
• The United States accounts for the largest market size for Autosomal Dominant Polycystic Kidney Disease, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
• Upcoming therapies such as Bardoxolone methyl, Tesevatinib/KD019, and RGLS8429 have the potential to create a significant positive shift in the Autosomal Dominant Polycystic Kidney Disease market size.
• Among the EU5 countries, the United Kingdom had the highest market size, with USD 79 million in 2021.
• Total diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease in the 7MM were found to be approximately 367,042 cases in the year 2021. The diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease are likely to change by 2032 in the forecast period.
• The United States accounted for approximately 142,709 diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease in the year 2021.
• In 2021, the total reported diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease in EU-5 countries were approximately 193,161 cases.
• In 2021, the UK accounted for the highest number of Autosomal Dominant Polycystic Kidney Disease diagnosed prevalent cases (67,419), followed by France (61,282) among EU-5 countries. In contrast, Italy accounts for the lowest number of cases of Autosomal Dominant Polycystic Kidney Disease diagnosed prevalent population in EU-5.

Get a Detailed Overview of the Evolving Autosomal Dominant Polycystic Kidney Disease Market Trends @
https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Autosomal Dominant Polycystic Kidney Disease therapies in the market. It also provides a detailed assessment of the Autosomal Dominant Polycystic Kidney Disease market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Autosomal Dominant Polycystic Kidney Disease drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Autosomal Dominant Polycystic Kidney Disease Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Autosomal Dominant Polycystic Kidney Disease patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Autosomal Dominant Polycystic Kidney Disease Epidemiology Segmented as -
• Total Diagnosed Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease
• Age-specific cases of Autosomal Dominant Polycystic Kidney Disease
• Mutation-specific cases of Autosomal Dominant Polycystic Kidney Disease

Get Key Insights Into the Evolving Autosomal Dominant Polycystic Kidney Disease Epidemiology Trends @
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autosomal Dominant Polycystic Kidney Disease market or expected to be launched during the study period. The analysis covers the market share by Autosomal Dominant Polycystic Kidney Disease drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Autosomal Dominant Polycystic Kidney Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Autosomal Dominant Polycystic Kidney Disease Market @
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Assessment
At present, there is no curative treatment for ADPKD and most available treatments focus on managing the associated complications, delaying kidney function decline, and slowing the cyst enlargement. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) are preferred by most specialists who treat hypertension in ADPKD patients. In individuals with ADPKD, these drugs may be more effective in preserving kidney function and preventing left ventricular hypertrophy than other therapies for hypertension.

Effective treatment requires the coordinated efforts of a team of specialists working together to systematically and comprehensively plan an affected individual's prescription. Such specialists may include primary care family physicians, pediatricians, or internists who collaborate with physicians specializing in disorders of the kidneys (nephrologists), surgical disorders of the urinary tract (urologists), dietitians, and/or other health care professionals. Genetic counseling may benefit affected individuals and their families.

Tolvaptan (Jynarque/Jinarc/Samsca) developed by Otsuka Pharmaceutical is the only FDA-approved therapy to treat adults with rapidly progressing ADPKD. With improved disease understanding to address the current unmet need for ADPKD, several companies like Reata Pharmaceuticals, Sanofi, Janssen Pharmaceuticals, and Regulus Therapeutics are conducting trials for molecules that target various pathways to control cyst formation or delay it.

Several major pharma and biotech companies developing therapies for Autosomal dominant polycystic kidney disease. Currently, Reata Pharmaceuticals is leading the therapeutics market with its Autosomal dominant polycystic kidney disease drug candidates in the most advanced stage of clinical development.

Leading Companies in the Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market Include
AceLink Therapeutics, Alebund Pharmaceuticals, Anakuria Therapeutics, Chinook Therapeutics, Galapagos NV, Healx, Janssen Pharmaceuticals, Kadmon Pharmaceuticals, Otsuka Pharmaceutical, Poxel, Reata Pharmaceuticals, Regulus Therapeutics, Sanofi, Xortx Therapeutics, and many others

Emerging and Marketed Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapies Covered in the Report Include
• GLPG2737: Galapagos NV
• Bardoxolone methyl: Reata Pharmaceuticals
• Jynarque/Jinarc/Samsca (tolvaptan): Otsuka Pharmaceutical
• Tesevatinib/KD019: Sanofi
• RGLS8429: Regulus Therapeutics
And Many More

Learn More About the Emerging Therapies and key Companies in the Autosomal Dominant Polycystic Kidney Disease Therapeutics Market @
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Autosomal Dominant Polycystic Kidney Disease Competitive Intelligence Analysis
4. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance
5. Autosomal Dominant Polycystic Kidney Disease Background and Overview
6. Autosomal Dominant Polycystic Kidney Disease Patient Journey
7. Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population
8. Autosomal Dominant Polycystic Kidney Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Autosomal Dominant Polycystic Kidney Disease Unmet Needs
10. Key Endpoints of Autosomal Dominant Polycystic Kidney Disease Treatment
11. Autosomal Dominant Polycystic Kidney Disease Marketed Products
12. Autosomal Dominant Polycystic Kidney Disease Emerging Therapies
13. Autosomal Dominant Polycystic Kidney Disease Seven Major Market Analysis
14. Attribute Analysis
15. Autosomal Dominant Polycystic Kidney Disease Market Outlook (7 major markets)
16. Autosomal Dominant Polycystic Kidney Disease Access and Reimbursement Overview
17. KOL Views on the Autosomal Dominant Polycystic Kidney Disease Market.
18. Autosomal Dominant Polycystic Kidney Disease Market Drivers
19. Autosomal Dominant Polycystic Kidney Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Indolent Lymphoma Market
https://www.delveinsight.com/report-store/indolent-lymphoma-market

Lipodystrophy Market
https://www.delveinsight.com/report-store/lipodystrophy-market

Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market

Anaplastic Astrocytoma Market
https://www.delveinsight.com/report-store/anaplastic-astrocytoma-market

Singapore Healthcare Outlook
https://www.delveinsight.com/report-store/singapore-healthcare-outlook-report

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market
https://www.delveinsight.com/report-store/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-market

Chronic Idiopathic Constipation Market
https://www.delveinsight.com/report-store/chronic-idiopathic-constipation-market

Hay Fever Conjunctivitis Market
https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market

Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market

Cerebral Infarction Market
https://www.delveinsight.com/report-store/cerebral-infarction-market

CART-related Neurotoxicity (NT) Market
https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market

Hernia Repair Devices Market
https://www.delveinsight.com/report-store/hernia-repair-devices-market

Bronchial Hyperreactivity Market
https://www.delveinsight.com/report-store/bronchial-hyperreactivity-market

Chronic Focal Epilepsy Market
https://www.delveinsight.com/report-store/chronic-focal-epilepsy-market

Dental Lasers Market
https://www.delveinsight.com/report-store/dental-lasers-market

Down Syndrome Market
https://www.delveinsight.com/report-store/down-syndrome-market

Extracorporeal Circulation System Market
https://www.delveinsight.com/report-store/extracorporeal-circulation-system-market

Failed Back Surgery Syndrome Market
https://www.delveinsight.com/report-store/failed-back-surgery-syndrome-market

Germ Cell Tumor Market
https://www.delveinsight.com/report-store/germ-cell-tumor-market

Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market

India Healthcare Outlook
https://www.delveinsight.com/report-store/india-healthcare-outlook-report

Insulin Glargine Biosimilar
https://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market

Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market

Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market

Nasolabial Fold Market
https://www.delveinsight.com/report-store/nasolabial-fold-market

Neuroleptic Malignant Syndrome Market
https://www.delveinsight.com/report-store/neuroleptic-malignant-syndrome-market

Pachyonychia Congenita Market
https://www.delveinsight.com/report-store/pachyonychia-congenita-market

Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market

Reactive Airway Disease Market
https://www.delveinsight.com/report-store/reactive-airway-disease-market

Seborrhea Market
https://www.delveinsight.com/report-store/seborrhea-market

Substance (Drug) Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market

Synchronous Endometrial and Ovarian Cancer (SEOC) Market
https://www.delveinsight.com/report-store/synchronous-endometrial-and-ovarian-cancer-seoc-market

Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Urinary Tract Infection Devices Market
https://www.delveinsight.com/report-store/urinary-tract-infection-devices-market

Varicose Veins Market
https://www.delveinsight.com/report-store/varicose-veins-market

Vulvodynia Market
https://www.delveinsight.com/report-store/vulvodynia-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.